Top

Published in:

01-11-2010 | Brief Report

Angiosarcoma following MammoSite^® partial breast irradiation

Authors: Samuel Andrews, Rebecca Wilcoxon, Jo Benda, Geraldine Jacobson

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

Angiosarcoma is a rare tumor of endothelial origin which commonly arises in small blood or lymphatic vessels. Its development in the treated breast following adjuvant external beam radiation is also rare. To our knowledge, there are no reported cases in the literature or MammoSite^® registry which describe the occurrence of angiosarcoma in the treated breast following MammoSite^® brachytherapy. This is a case report of a 74 year old female who developed angiosarcoma 4 years after receiving MammoSite^® balloon brachytherapy following surgical resection of a T1mic N0 M0 infiltrating ductal carcinoma.

Marchal C, Weber B, de Lafontan B, Resbeut M, Mignotte H, du Chatelard PP, Cutuli B, Reme-Saumon M, Broussier-Leroux A, Chaplain G et al (1999) Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys 44(1):113–119CrossRefPubMed

Offersen BV, Overgaard M, Kroman N, Overgaard J (2009) Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol 90(1):1–13CrossRefPubMed

Nelson JC, Beitsch PD, Vicini FA, Quiet CA, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Whitworth PW, Fine RE et al (2009) Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg 198(1):83–91CrossRefPubMed

Stewart FW, Treves N (1948) Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1(1):64–81CrossRefPubMed

Cahan WG, Woodard HQ et al (1948) Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1(1):3–29CrossRefPubMed

Hamels J, Blondiau P, Mirgaux M (1981) Cutaneous angiosarcoma arising in a mastectomy scar after therapeutic irradiation. Bull Cancer 68(4):353–356PubMed

Davies JD, Rees GJ, Mera SL (1983) Angiosarcoma in irradiated post-mastectomy chest wall. Histopathology 7(6):947–956CrossRefPubMed

Strobbe LJ, Peterse HL, van Tinteren H, Wijnmaalen A, Rutgers EJ (1998) Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 47(2):101–109CrossRefPubMed

Pendlebury SC, Bilous M, Langlands AO (1995) Sarcomas following radiation therapy for breast cancer: a report of three cases and a review of the literature. Int J Radiat Oncol Biol Phys 31(2):405–410PubMed

10.

Wijnmaalen A, van Ooijen B, van Geel BN, Henzen-Logmans SC, Treurniet-Donker AD (1993) Angiosarcoma of the breast following lumpectomy, axillary lymph node dissection, and radiotherapy for primary breast cancer: three case reports and a review of the literature. Int J Radiat Oncol Biol Phys 26(1):135–139PubMed

11.

Stokkel MP, Peterse HL (1992) Angiosarcoma of the breast after lumpectomy and radiation therapy for adenocarcinoma. Cancer 69(12):2965–2968CrossRefPubMed

12.

Wang XY, Jakowski J, Tawfik OW, Thomas PA, Fan F (2009) Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 13(3):147–150CrossRefPubMed

Title: Angiosarcoma following MammoSite® partial breast irradiation
Authors: Samuel Andrews
Rebecca Wilcoxon
Jo Benda
Geraldine Jacobson
Publication date: 01-11-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0948-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

The G12 family proteins upregulate matrix metalloproteinase-2 via p53 leading to human breast cell invasion

Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation

Association of TGFB1 -509 C>T polymorphism with breast cancer: evidence from a meta-analysis involving 23,579 subjects

UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons

Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109

Keynote webinar | Spotlight on antibody–drug conjugates in cancer